Conclusion
Anosmia and dysgeusia are prevalent symptoms of COVID19 disease, especially amongst females. Further cohort or case control studies are needed to establish the association and risk factors of anosmia and dysgeusia with the disease ideally involving a control group. Definitive mechanism of action and diagnostic value of anosmia and dysgeusia remain to be verified in future studies. Effective treatment regimen for anosmia and dysgeusia post COVID should be investigated in randomised controlled trials to enhance patient’s quality of life.